Monthly Archives: November 2011

International group seeks Brown University’s help in retracting controversial Paxil study

Share The international research organization Healthy Skepticism has called on Brown University to help convince a psychiatric journal to retract the controversial Paxil trial that I wrote about in Side Effects, according to the Brown Daily Herald. The principal investigator … Continue reading

Posted in antidepressants, conflicts of interest, drug marketing, ghostwriting, pharmaceutical industry, scientific journal retractions, scientific misconduct | Tagged , , , , , , , | 4 Comments

New drug industry partnership with hospitals could jeopardize patient care

Share We’ve all signed those vague privacy statements when visiting our local hospital for medical care. But how many of us have actually read the fine print and understand that the most sensitive details of our medical lives may be … Continue reading

Posted in biotech industry, clinical trials, conflicts of interest, patient care, pharmaceutical industry, Uncategorized, university industry collaboration | Tagged , , , , , , , | 1 Comment

Allegations of fraud and extensive ghostwriting form core of upcoming Texas case against Johnson & Johnson

Share On November 28, the Texas Attorney General is expected to begin a landmark trial against Johnson & Johnson on charges that the pharmaceutical giant “subverted scientific integrity” by paying off academic psychiatrists and state officials to boost the use … Continue reading

Posted in antipsychotic drugs, conflicts of interest, drug marketing, ghostwriting, patient care, pharmaceutical industry, scientific misconduct, Uncategorized | Tagged , , , , | 6 Comments